Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other*
暂无分享,去创建一个
A. Prat | N. Seidah | Y. Jacob | A. Chamberland | S. Benjannet | J. Hamelin | R. Essalmani | G. Mayer | Steve Poirier | M. Asselin | S. Sisodia | M. Canuel | J. Marcinkiewicz | J. Guillemot | Chutikarn Butkinaree | Anna Roubtsova | C. Butkinaree | Maryssa Canuel
[1] Jonathan C. Cohen,et al. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor , 2008, Proceedings of the National Academy of Sciences.
[2] N. Tommerup,et al. Molecular Identification of a Novel Candidate Sorting Receptor Purified from Human Brain by Receptor-associated Protein Affinity Chromatography* , 1997, The Journal of Biological Chemistry.
[3] A. Prat,et al. Deletion of the Gene Encoding Proprotein Convertase 5/6 Causes Early Embryonic Lethality in the Mouse , 2006, Molecular and Cellular Biology.
[4] J. Horton,et al. Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells* , 2007, Journal of Biological Chemistry.
[5] Jonathan C. Cohen,et al. ARH Is a Modular Adaptor Protein That Interacts with the LDL Receptor, Clathrin, and AP-2* , 2002, The Journal of Biological Chemistry.
[6] Alexander Pertsemlidis,et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.
[7] Rachel M. Devay,et al. Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9* , 2012, The Journal of Biological Chemistry.
[8] T. Leren. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. , 2014, Atherosclerosis.
[9] J. Breslow,et al. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[10] Mahak Sharma,et al. Amyloid Precursor-Like Protein 2 Increases the Endocytosis, Instability, and Turnover of the H2-Kd MHC Class I Molecule1 , 2008, The Journal of Immunology.
[11] W. Dai,et al. APLP1 and APLP2, members of the APP family of proteins, behave similarly to APP in that they associate with NMDA receptors and enhance NMDA receptor surface expression , 2015, Journal of neurochemistry.
[12] D. Hanahan,et al. cDNA sequence of neuroendocrine protein 7B2 expressed in beta cell tumors of transgenic mice. , 2009, International journal of peptide and protein research.
[13] E. Settembre,et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH , 2011, EMBO reports.
[14] N. Seidah,et al. Effects of the Prosegment and pH on the Activity of PCSK9 , 2010, The Journal of Biological Chemistry.
[15] J. Nyengaard,et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury , 2007, Nature Neuroscience.
[16] Tommaso Fasano,et al. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. , 2009, Atherosclerosis.
[17] Jay D. Horton,et al. Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver* , 2004, Journal of Biological Chemistry.
[18] Jonathan C. Cohen,et al. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR , 2012, Journal of Lipid Research.
[19] Annik Prat,et al. The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR , 2007, Traffic.
[20] Annik Prat,et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte‐specific low‐density lipoprotein receptor degradation and critical role in mouse liver regeneration , 2008, Hepatology.
[21] F. Raal,et al. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. , 2014, Annual review of medicine.
[22] Louise Wickham,et al. Post-translational Processing of β-Secretase (β-Amyloid-converting Enzyme) and Its Ectodomain Shedding , 2001, The Journal of Biological Chemistry.
[23] Jiandie D. Lin,et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion , 2013, eLife.
[24] A. Prat,et al. In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9* , 2010, The Journal of Biological Chemistry.
[25] R. De Francesco,et al. Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation* , 2007, Journal of Biological Chemistry.
[26] Rachel M. Devay,et al. Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2) , 2013, The Journal of Biological Chemistry.
[27] A. Prat,et al. The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.
[28] N. Seidah,et al. Loss- and Gain-of-function PCSK9 Variants , 2012, The Journal of Biological Chemistry.
[29] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[30] P. Vidalain,et al. Benchmarking a luciferase complementation assay for detecting protein complexes , 2011, Nature Methods.
[31] J. Lippincott-Schwartz,et al. Brefeldin A: insights into the control of membrane traffic and organelle structure , 1992, The Journal of cell biology.
[32] Xin-Fu Zhou,et al. The Intracellular Domain of Sortilin Interacts with Amyloid Precursor Protein and Regulates Its Lysosomal and Lipid Raft Trafficking , 2013, PloS one.
[33] S. Sisodia,et al. Amyloid precursor-like protein 2 (APLP2) is modified by the addition of chondroitin sulfate glycosaminoglycan at a single site. , 1994, The Journal of biological chemistry.
[34] S. Sisodia,et al. Novel Regulation of Chondroitin Sulfate Glycosaminoglycan Modification of Amyloid Precursor Protein and Its Homologue, APLP2 (*) , 1995, The Journal of Biological Chemistry.
[35] O. Mors,et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. , 2014, Cell metabolism.
[36] A. Prat,et al. Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation , 2009, The Journal of Biological Chemistry.
[37] R. Hampton. ER-associated degradation in protein quality control and cellular regulation. , 2002, Current opinion in cell biology.
[38] Mahak Sharma,et al. Mechanism for Amyloid Precursor-like Protein 2 Enhancement of Major Histocompatibility Complex Class I Molecule Degradation* , 2009, The Journal of Biological Chemistry.
[39] Annik Prat,et al. The biology and therapeutic targeting of the proprotein convertases , 2012, Nature Reviews Drug Discovery.
[40] S. Stagg,et al. New Insights into the Structural Mechanisms of the COPII Coat , 2010, Traffic.
[41] D. Price,et al. Generation of APLP2 KO Mice and Early Postnatal Lethality in APLP2/APP Double KO Mice , 1997, Neurobiology of Aging.
[42] A. Prat,et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[43] N. Seidah,et al. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. , 2013, Current pharmaceutical design.
[44] P. Madsen,et al. The sortilin cytoplasmic tail conveys Golgi–endosome transport and binds the VHS domain of the GGA2 sorting protein , 2001, The EMBO journal.
[45] T. Ranheim,et al. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly , 2007, BMC Cell Biology.
[46] N. Seidah,et al. The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway* , 2012, The Journal of Biological Chemistry.
[47] A. Prat,et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. , 2012, Atherosclerosis.
[48] Rachel M. Devay,et al. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function , 2015, PloS one.
[49] A. Prat,et al. ZYMOGEN CLEAVAGE AND EFFECTS ON THE LOW DENSITY LIPOPROTEIN (LDL) RECEPTOR AND LDL CHOLESTEROL , 2004 .
[50] Xiayang Qiu,et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia , 2007, Nature Structural &Molecular Biology.
[51] C. Morales,et al. The inactivation of the sortilin gene leads to a partial disruption of prosaposin trafficking to the lysosomes. , 2009, Experimental cell research.
[52] R. Schekman,et al. Bi-directional protein transport between the ER and Golgi. , 2004, Annual review of cell and developmental biology.
[53] L. Bernier,et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[54] J. Horton,et al. Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells* , 2009, Journal of Biological Chemistry.
[55] A. Prat,et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) , 2013, PloS one.
[56] Jonathan C. Cohen,et al. Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein , 2001, Science.
[57] M. Vidal,et al. Comparative analysis of virus-host interactomes with a mammalian high-throughput protein complementation assay based on Gaussia princeps luciferase. , 2012, Methods.
[58] N. Seidah,et al. PCSK9: A Key Modulator of Cardiovascular Health , 2014, Circulation research.
[59] K. Berge,et al. Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain. , 2010, Molecular genetics and metabolism.
[60] R. Hammer,et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. , 2006, The Journal of clinical investigation.
[61] A. Prat,et al. Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[62] N. Seidah,et al. Post-translational processing of b -secretase (BACE) and its ectodomain shedding: the pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid A b production , 2000 .